Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Medlive Technology Co., Ltd. ( (HK:2192) ) has issued an update.
Medlive Technology has scheduled a board meeting for 26 March 2026 to review and approve the annual results for the financial year ended 31 December 2025. The board will also consider the recommendation and payment of a final dividend, signaling an upcoming update on the company’s financial performance and potential shareholder returns.
The meeting outcome will provide investors and stakeholders with an important snapshot of Medlive Technology’s operational and financial health over the past year. Any decision on a final dividend could influence market perception of the company’s cash flow strength and capital allocation priorities.
The most recent analyst rating on (HK:2192) stock is a Buy with a HK$11.00 price target. To see the full list of analyst forecasts on Medlive Technology Co., Ltd. stock, see the HK:2192 Stock Forecast page.
More about Medlive Technology Co., Ltd.
Medlive Technology Co., Ltd. is a Cayman Islands–incorporated company listed in Hong Kong under stock code 2192. It operates in the technology sector and is governed by a board comprising executive, non-executive and independent non-executive directors, led by chairwoman and chief executive officer Tian Liping.
Average Trading Volume: 4,436,245
Technical Sentiment Signal: Sell
Current Market Cap: HK$6.5B
See more data about 2192 stock on TipRanks’ Stock Analysis page.